Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Chronic immune activation is a central feature of HIV-infection, and the degree of activated
T-cells is a better predictor of disease progression and mortality than plasma viral load.
The study hypothesis is that the anti-inflammatory substance etoricoxib will dampen chronic
immune activation and improve the effect of T-cell dependent vaccines in HIV-1 infected
patients.
The aim of the present study is to explore the efficacy of the study drug on markers of
immune activation and vaccine responses, as well as safety of the study drug, in HIV-infected
patients not receiving antiretroviral therapy and in patients on long-term effective ART who
had CD4 counts < 500.